CLINICAL TRIALS PROFILE FOR VIIBRYD

All Clinical Trials for Viibryd

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01473381 ↗	Safety and Efficacy of Vilazodone in Major Depressive Disorder	Completed	Forest Laboratories	Phase 4	2011-12-01	The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder.
NCT01473394 ↗	Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder	Completed	Forest Laboratories	Phase 4	2011-12-01	The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder.
NCT01573598 ↗	Safety and Efficacy of Vilazodone in Major Depressive Disorder	Completed	Forest Laboratories	Phase 4	2012-04-01	Safety and Efficacy of Vilazodone in Major Depressive Disorder
NCT01574183 ↗	Vilazodone Treatment for Marijuana Dependence	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	2012-08-01	Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of vilazodone for reducing marijuana use in marijuana-dependent adults. A contingency management intervention (CM)and motivational enhancement therapy (MET)will be incorporated to encourage study engagement and retention, and genomic DNA will be extracted to characterize subjects according to polymorphisms of genes potentially relevant to the activity of vilazodone. It is hypothesized that vilazodone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.
NCT01574183 ↗	Vilazodone Treatment for Marijuana Dependence	Completed	Medical University of South Carolina	Phase 2	2012-08-01	Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of vilazodone for reducing marijuana use in marijuana-dependent adults. A contingency management intervention (CM)and motivational enhancement therapy (MET)will be incorporated to encourage study engagement and retention, and genomic DNA will be extracted to characterize subjects according to polymorphisms of genes potentially relevant to the activity of vilazodone. It is hypothesized that vilazodone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.
NCT01608295 ↗	Vilazodone for Treatment of Geriatric Depression	Completed	Forest Laboratories	Phase 4	2012-07-01	The purpose of this study is to examine the effects of vilazodone for the treatment of depression in older adults.

Clinical Trial Conditions for Viibryd

Condition Name

Condition Name for Viibryd
Intervention	Trials
Major Depressive Disorder	9
Major Depressive Disorder (MDD)	1
Marijuana Dependence	1
Memory Impairment	1

Condition MeSH

Condition MeSH for Viibryd
Intervention	Trials
Depressive Disorder, Major	10
Depressive Disorder	10
Depression	10
Disease	8

Clinical Trial Locations for Viibryd

Trials by Country

Trials by Country for Viibryd
Location	Trials
United States	134
Ukraine	5
Canada	4
Serbia	4
Finland	3

Trials by US State

Trials by US State for Viibryd
Location	Trials
Texas	7
New York	7
Florida	7
California	7
Washington	6

Clinical Trial Progress for Viibryd

Clinical Trial Phase

Clinical Trial Phase for Viibryd
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	4
Phase 2	2

Clinical Trial Status

Clinical Trial Status for Viibryd
Clinical Trial Phase	Trials
Completed	13
Terminated	1
Unknown status	1

Clinical Trial Sponsors for Viibryd

Sponsor Name

Sponsor Name for Viibryd
Sponsor	Trials
Forest Laboratories	13
University of California, Los Angeles	1
University of Pennsylvania	1

Sponsor Type

Sponsor Type for Viibryd
Sponsor	Trials
Industry	13
Other	9
NIH	1